Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Acumen Exercises Option for Up to Two JCR-Enabled AD Candidates
JCR Pharmaceuticals said on June 17 that US biotech Acumen Pharmaceuticals has exercised its exclusive option to globally develop, manufacture, and commercialize up to two Alzheimer’s drug candidates incorporating its blood-brain barrier (BBB)-penetrating technology. The option stems from a collaboration…
To read the full story
Related Article
BUSINESS
- Marubeni Pharma Launches OAB Drug Gemtesa in Taiwan
September 29, 2026
- Taisho Pulls Plug on Clarith Tablets, Shifts to AG
September 29, 2026
- Tanabe Licenses Anti-IL-33 Antibody to Tolerance
September 29, 2026
- Roche Axes Emugrobart in Obesity; Chugai to Revive SMA Program
September 29, 2026
- Nipro, Mikasa Finalize 2-Plant Transfer despite Compliance Issue
September 29, 2026
The development of Boehringer Ingelheim’s survodutide is gathering pace, putting the GLP-1/glucagon receptor agonist in contention to become the next…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…